217 results
Page 3 of 11
8-K
EX-99.1
krpjatcasm2eq
17 Apr 23
Kineta Unveils New VISTA Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update at AACR Annual Meeting 2023
11:09am
8-K
EX-99.1
vcsxnynet
12 Apr 23
Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors
7:01am
8-K
EX-99.1
hjsg8yb3i recc
3 Apr 23
Kineta to Present at 22nd Annual Needham Healthcare Conference
7:01am
8-K
EX-99.1
gl98gaj826z4lqb15mxs
31 Mar 23
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-99.1
q9umq hig3
31 Mar 23
Regulation FD Disclosure
12:00am
8-K
EX-99.5
ux7v57n5lbwhrc98w
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.1
so129w9l
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.6
rh1uvkx 9ms1ej3
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
hz031yr6nomxvoqh5yy
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K/A
iekva3m2dgo
16 Dec 22
Other Events
2:58pm
8-K
r1vbip749t
15 Dec 22
Completion of Acquisition or Disposition of Assets
6:11am
8-K
f15cx tbwl
13 Dec 22
Submission of Matters to a Vote of Security Holders
4:02pm
425
iachmybul89a 0gqg
6 Dec 22
Business combination disclosure
4:04pm
8-K
EX-99.1
g8td1
6 Dec 22
Regulation FD Disclosure
4:02pm
8-K
p1i 1r4ex7lvnem
6 Dec 22
Regulation FD Disclosure
4:02pm
425
un5tk7ne4s ajhhj
5 Dec 22
Business combination disclosure
9:28am
8-K
EX-99.1
wyfenw3er 5p
5 Dec 22
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
9:27am
8-K
mztoe7eq37 5syc9abhu
5 Dec 22
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
9:27am
425
k6f10ey o7y2b
1 Dec 22
Business combination disclosure
4:04pm